Synteract acquires KinderPharm to be ‘one-stop shop’ for pediatric clinical trials

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/KatarzynaBialasiewicz)
(Image: Getty/KatarzynaBialasiewicz)

Related tags Synteract KinderPharm Pediatrics Drug development Clinical trials

Synteract’s clients will benefit from a single source model, says CEO, following the acquisition of KinderPharm, a PA-based CRO focused on all phases of pediatric drug development.

Synteract CEO Steve Powell said the combined contract research organization (CRO) will offer biopharma a “one-stop shop solution for bringing their pediatric clinical trials​ to life.”

“Through the KinderPharm integration, our clients will be able to benefit from a single source model,” ​Powell told us.

The single source model will offer pharmacometric modeling and clinical trial simulation technologies, including pharmacokinetic data analysis, PK/PD modeling, physiologically-based PK modeling, and population PK analysis.

Powell added, “KinderPharm also brings a focus on the development of novel and rare pediatric drugs through pediatric formulation and juvenile toxicology expertise, as well as extensive US and European pediatric regulatory experience.”

Martin Graham, PhD, KinderPharm CEO and founder, will join the team as senior vice president of pediatric development, leading Synteract’s Center of Pediatric Development. 

Graham will be joined by KinderPharm’s Lynne Georgopoulos, vice president pediatric development, Americas, and Synteract’s Dr. Martine Dehlinger-Kremer, vice president pediatric development, Europe, to build a leadership team.

Synteract earlier this year announced​ pediatrics as one of its “therapeutic centers of development.”​ Other centers include oncology, neuro-degenerative disorders, rare and orphan diseases, as well as dermatology – following the acquisition​ of Cu-Tech in July.

KinderPharm was previously involved in a strategic alliance with Worldwide Clinical Trials​ (WCT). Announced in April of this year, the alliance established a center of excellence for pediatric drug development and research. The relationship had since been dissolved.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Related suppliers

Follow us


View more